Viva Biotech Holdings Cash Flow-to-Debt Ratio
Viva Biotech Holdings cash flow-to-debt ratio. Viva Biotech Holdings (VB0) has a Cash Flow-to-Debt Ratio of 0.04x as of June 2023, meaning its operating cash flow of €158.72 Million could theoretically repay 0% of its total liabilities (€4.51 Billion) in one year. Check VB0 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Viva Biotech Holdings (2016–2024)
Cash flow-to-debt ratio of Viva Biotech Holdings from 2016 to 2024. Historical debt coverage capacity for Viva Biotech Holdings across 9 annual periods. Check total reinvestment intensity of Viva Biotech Holdings to assess the company's total reinvestment commitment from operating cash flow.
Viva Biotech Holdings Cash Flow-to-Debt Ratio by Year (2016–2024)
Viva Biotech Holdings cash flow-to-debt ratio by year from 2016 to 2024. Year-by-year debt coverage analysis for Viva Biotech Holdings. For the full cash flow conversion analysis, see Viva Biotech Holdings (VB0) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.12x | €373.99 Million | €3.23 Billion | ▲ +13.5% |
| 2023 | 0.10x | €383.40 Million | €3.76 Billion | ▲ +13.9% |
| 2022 | 0.09x | €386.05 Million | €4.32 Billion | ▲ +374.8% |
| 2021 | 0.02x | €77.83 Million | €4.13 Billion | ▲ +91.8% |
| 2020 | 0.01x | €43.18 Million | €4.40 Billion | ▼ -97.4% |
| 2019 | 0.38x | €46.01 Million | €121.39 Million | ▲ +769.8% |
| 2018 | 0.04x | €12.11 Million | €277.90 Million | ▼ -92.2% |
| 2017 | 0.56x | €27.89 Million | €49.64 Million | ▼ -32.6% |
| 2016 | 0.83x | €21.12 Million | €25.32 Million | — |